| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Net loss | ||||||
- | - | -3,314 | - | |||
Cash flows from operating activities: | ||||||
Net loss | ||||||
-10,654 | -12,372 | - | -4,132 | |||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation | ||||||
13 | 5 | 3 | 0 | |||
Share based compensation | ||||||
3,529 | 5,435 | 1,323 | 2,657 | |||
Changes in operating assets and liabilities: | ||||||
Accounts receivable | ||||||
-8 | 0 | 0 | 0 | |||
Prepaid expenses and other | ||||||
-65 | 213 | -4 | 19 | |||
Deposits | ||||||
3 | 18 | - | - | |||
Deposits | ||||||
- | - | 0 | 2 | |||
Deferred offering costs | ||||||
- | -759 | 734 | 25 | |||
Accounts payable and accrued expenses | ||||||
141 | -443 | 545 | 269 | |||
Other current liabilities | ||||||
-18 | - | - | - | |||
Net cash used in operating activities | ||||||
-6,918 | -6,846 | -2,171 | -1,248 | |||
Cash flows from investing activities: | ||||||
Additions to property and equipment | ||||||
33 | 22 | 5 | 4 | |||
Additions to intellectual property | ||||||
111 | 80 | 57 | 84 | |||
Additions to research and development supplies | ||||||
801 | - | - | - | |||
Net cash used in investing activities | ||||||
-946 | -103 | -63 | -89 | |||
Proceeds from issuances of stock | ||||||
1,267 | 15,389 | 793 | 2,705 | |||
Net cash provided by financing activities | ||||||
1,267 | 15,389 | 793 | 2,705 | |||
Net increase (decrease) in cash | ||||||
-6,598 | 8,439 | -1,441 | - | |||
Net increase (decrease) in cash | ||||||
- | - | - | 1,368 | |||